



(12) Translation of
european patent specification

(11) NO/EP 2563771 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 401/06 (2006.01)
A61K 31/4439 (2006.01)
A61P 9/00 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.04.11
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.11.25
(86)	European Application Nr.	11772772.7
(86)	European Filing Date	2011.04.22
(87)	The European Application's Publication Date	2013.03.06
(30)	Priority	2010.04.24, US, 327663 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Viamet Pharmaceuticals, Inc., 4505 Emperor Boulevard, Suite 300, Durham, NC 27703, US-USA
(72)	Inventor	HOEKSTRA, William, J., 7 Treviso Place, Durham, NC 27707, US-USA SCHOTZINGER, Robert, J., 7000 Potomac Court, Raleigh, NC 27613, US-USA RAFFERTY, Stephen, William, 7321 Abron Drive, Durham, NC 27713, US-USA
(74)	Agent or Attorney	Tandbergs Patentkontor AS, Postboks 1570 Vika, 0118 OSLO, Norge


(54)	Title	METALLOENZYME INHIBITOR COMPOUNDS
(56)	References Cited:	JP-A- 2000 344 744 US-A- 4 616 026 US-A- 5 084 465 ETO H ET AL: "New antifungal 1,2,4-triazoles with difluoro(heteroaryl)methyl moiety", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 48, no. 7, 1 July 2000 (2000-07-01), pages 982-990, XP002197708, ISSN: 0009-2363 ETO, HIROMICHI ET AL.: 'New Antifungal 1,2,4-Triazoles with Difluoro(heteroary 1)methyl Moiety' CHEMICAL AND PHARMACEUTICAL BULLETIN vol. 48, no. 7, 2000, pages 982 - 990

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. En forbindelse med formel (I), eller et salt derav, hvor:

5



(I)

MBG er eventuelt substituert tetrazolyl, eventuelt substituert triazolyl, eller eventuelt substituert pyrazolyl;

R₁ er halogen;

10

R₂ er halogen;

hver R₃ er uavhengig alkyl, cyano, halogenalkyl, alkoksy, halogen, halogen-alkoksy,

R₄ er aryl som eventuelt er substituert med 0, 1, 2 eller 3 uavhengig R₃;

R₅ er H eller -C(O)alkyl, eventuelt substituert med amino;

15

n er 0, 1, 2 eller 3.

2. Forbindelse ifølge krav 1, hvor R₁ er fluor.

3. Forbindelse ifølge krav 1, hvor R₂ er fluor.

20

4. Forbindelse ifølge krav 1, hvor R₁ og R₂ er fluor.

5. Forbindelse ifølge krav 1, hvor R₄ er fenyl eventuelt substituert med 0, 1, 2 eller 3 uavhengig R₃.

25

6. Forbindelse ifølge krav 1, hvor R₄ er fenyl eventuelt substituert med 0, 1, 2 eller 3 uavhengig halogen.

7. Forbindelse ifølge krav 1, hvor R₄ er fenyl eventuelt substituert med 0, 1, 2 eller 3 uavhengig fluor.

30

8. Forbindelse ifølge krav 1, hvor R₄ er 2,4-difluorfenyl.

9. Forbindelse ifølge krav 1, hvor R₅ er H.

10. Forbindelse ifølge krav 1, hvor R₅ er aminosubstitueret acyl.

5 **11.** Forbindelse ifølge krav 1, hvor:

R₁ er fluor;

R₂ er fluor;

R₄ er 2,4-difluorfenyl; og

10 R₅ er H.

12. Forbindelse ifølge krav 1, hvor:

15 hver R₃ er uafhængig cyano, halogenalkyl, alkoksy, halogen, halogenalkoksy, og
n er 1 eller 2.

13. Forbindelse ifølge krav 11, hvor:

20 hver R₃ er uafhængig cyano, halogenalkyl, alkoksy, halogen, halogenalkoksy, og
n er 1.

14. Forbindelse ifølge krav 1, som er én af:

25 4-(6-(2-(2,4-difluorfenyl)-1,1-difluor-2-hydroksy-3-(1*H*-tetrazol-1-yl)propyl)-
pyridin-3-yl)benzonitril (**1**);

2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)-1-(5-(4-(trifluormetyl)-
fenyl)pyridin-2-yl)propan-2-ol (**2**);

3-(6-(2-(2,4-difluorfenyl)-1,1-difluor-2-hydroksy-3-(1*H*-tetrazol-1-yl)propyl)-
pyridin-3-yl)benzonitril (**3**);

30 2-(2,4-difluorfenyl)-1,1-difluor-1-(5-(4-isopropoksyfenyl)pyridin-2-yl)-3-(1*H*-
tetrazol-1-yl)propan-2-ol (**4**);

2-(2,4-difluorfenyl)-1,1-difluor-1-(5-(4-fluorfenyl)pyridin-2-yl)-3-(1*H*-tetrazol-
1-yl)propan-2-ol (**5**);

35 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)-1-(5-(3-(trifluormetoksy)-
fenyl)pyridin-2-yl)propan-2-ol (**6**);

2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)-1-(5-(4-(trifluormetoksy)-
fenyl)pyridin-2-yl)propan-2-ol (**7**);

- 1-(5-(3-klorfenyl)pyridin-2-yl)-2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)propan-2-ol (**8**);
- 1-(5-(4-klorfenyl)pyridin-2-yl)-2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)propan-2-ol (**9**);
- 5 2-(2,4-difluorfenyl)-1-(5-(2,5-difluorfenyl)pyridin-2-yl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)propan-2-ol (**10**);
- 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoretoksy)fenyl)pyridin-2-yl)propan-2-ol (**11**);
- 2-(2,4-difluorfenyl)-1,1-difluor-1-(5-(4-(2,2,3,3,3-pentafluorpropoksy)fenyl)-pyridin-2-yl)-3-(1*H*-tetrazol-1-yl)propan-2-ol (**12**);
- 10 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoretoksy)fenyl)pyridin-2-yl)propan-2-yl3-aminopropanat (**13**);
- 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoretoksy)fenyl)pyridin-2-yl)propan-2-yl2-aminoacetathydroklorid (**14**);
- 15 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-pyrazol-3-yl)-1-(5-(4-(trifluormetyl)-fenyl)pyridin-2-yl)propan-2-ol (**15**);
- 2-(2,4-difluorfenyl)-1,1-difluor-1-(5-(4-fluorfenyl)pyridin-2-yl)-3-(1*H*-1,2,4-triazol-1-yl)propan-2-ol (**16**);
- 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-1,2,4-triazol-1-yl)-1-(5-(4-(2,2,2-trifluoretoksy)fenyl)pyridin-2-yl)propan-2-ol (**17**);
- 20 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-1,2,4-triazol-1-yl)-1-(5-(4-(trifluormetoksy)fenyl)pyridin-2-yl)propan-2-ol (**18**);
- 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-1,2,3-triazol-1-yl)-1-(5-(4-(trifluormetoksy)fenyl)pyridin-2-yl)propan-2-ol (**19**);
- 25 2-(2,4-difluorfenyl)-1,1-difluor-3-(2-*H*-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoretoksy)fenyl)pyridin-2-yl)propan-2-ol (**20**);
- 2-(2,4-difluorfenyl)-1,1-difluor-3-(2-*H*-tetrazol-1-yl)-1-(5-(3-fluorfenyl)pyridin-2-yl)propan-2-ol (**21**);
- 2-(2,4-difluorfenyl)-1,1-difluor-3-(2-*H*-tetrazol-1-yl)-1-(5-(4-(trifluormetyl)-fenyl)pyridin-2-yl)propan-2-ol (**22**);
- 30 2-(2,4-difluorfenyl)-1,1-difluor-3-(1*H*-1,2,3-triazol-1-yl)-1-(5-(4-(trifluormetyl)fenyl)pyridin-2-yl)propan-2-ol (**23**);
- 4-(6-(2-(2,4-difluorfenyl)-1,1-difluor-2-hidroksy-3-(1*H*-tetrazol-1-yl)propyl)-pyridin-3-yl)fenol (**24**);
- 35 2-(2,4-difluorfenyl)-1,1-difluor-1-(5-(3-isopropylfenyl)pyridin-2-yl)-3-(1*H*-tetrazol-1-yl)propan-2-ol (**25**);
- 2-(2,4-difluorfenyl)-1-(5-(3,4-difluorfenyl)pyridin-2-yl)-1,1-difluor-3-(1*H*-tetrazol-1-yl)propan-2-ol (**26**);

1-(5-(3-(difluormetoksy)fenyl)pyridin-2-yl)-2-(2,4-difluorfenyl)-1,1-difluor-3-(1H-tetrazol-1-yl)propan-2-ol (27);

2-(2,4-difluorfenyl)-1,1-difluor-3-(1H-tetrazol-1-yl)-1-(5-(4-((trifluormetyl)tio)fenyl)pyridin-2-yl)propan-2-ol (28).

5

15. En sammensetning som omfatter en forbindelse ifølge krav 1, og en farmasøytisk akseptabel bærer.